Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

26.10.2016: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC) - WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, entered into a research collaboration with Nordic Nanovector ASA, Oslo, Norway, a biotech company focusing on the development and commercialization of novel targeted therapeutics in hematology and oncology. ....More




Seite gelesen: 2616 | Heute: 214